Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GBIO |
---|---|---|
09:32 ET | 9235 | 3.8 |
09:41 ET | 1500 | 3.78 |
09:43 ET | 140 | 3.8523 |
09:50 ET | 2422 | 3.87 |
10:01 ET | 109 | 3.9199 |
10:03 ET | 200 | 3.8756 |
10:06 ET | 300 | 3.85 |
10:08 ET | 112 | 3.8742 |
10:17 ET | 102 | 3.8823 |
10:32 ET | 300 | 3.85 |
10:35 ET | 250 | 3.8699 |
10:50 ET | 1300 | 3.83 |
11:09 ET | 500 | 3.815 |
11:38 ET | 525 | 3.78 |
12:23 ET | 2003 | 3.835 |
12:27 ET | 146 | 3.83 |
12:38 ET | 5278 | 3.8 |
12:39 ET | 100 | 3.81 |
12:43 ET | 100 | 3.81 |
12:45 ET | 100 | 3.81 |
12:50 ET | 712 | 3.795 |
12:54 ET | 100 | 3.795 |
01:08 ET | 100 | 3.8 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Generation Bio Co | 250.8M | -1.5x | --- |
Century Therapeutics Inc | 259.3M | -1.4x | --- |
Design Therapeutics Inc | 254.2M | -4.2x | --- |
Pyxis Oncology Inc | 245.5M | -3.0x | --- |
Quantum-Si Inc | 263.7M | -2.8x | --- |
Aldeyra Therapeutics Inc | 243.0M | -7.9x | --- |
Generation Bio Co. is a biotechnology company. The Company is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The Company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). The Company is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types. Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $250.8M |
---|---|
Revenue (TTM) | $10.0M |
Shares Outstanding | 66.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.94 |
EPS | $-2.56 |
Book Value | $3.07 |
P/E Ratio | -1.5x |
Price/Sales (TTM) | 25.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,820.04% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.